Humacyte Stock Buy Hold or Sell Recommendation
| HUMA Stock | USD 4.49 0.11 2.51% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Humacyte is 'Strong Sell'. Macroaxis provides Humacyte buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Humacyte positions.
Check out Humacyte Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide. In addition, we conduct extensive research on individual companies such as Humacyte and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Humacyte |
Execute Humacyte Buy or Sell Advice
The Humacyte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Humacyte. Macroaxis does not own or have any residual interests in Humacyte or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Humacyte's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Humacyte Trading Alerts and Improvement Suggestions
| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 1.56 M. | |
| Humacyte currently holds about 189.04 M in cash with (73.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
| Roughly 27.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: HUMA INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
Humacyte Returns Distribution Density
The distribution of Humacyte's historical returns is an attempt to chart the uncertainty of Humacyte's future price movements. The chart of the probability distribution of Humacyte daily returns describes the distribution of returns around its average expected value. We use Humacyte price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Humacyte returns is essential to provide solid investment advice for Humacyte.
| Mean Return | -0.4 | Value At Risk | -8.43 | Potential Upside | 8.38 | Standard Deviation | 5.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Humacyte historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Humacyte Stock Institutional Investors
| Shares | D. E. Shaw & Co Lp | 2024-06-30 | 586 K | Monashee Investment Management Llc | 2024-09-30 | 535 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 463.7 K | Lpl Financial Corp | 2024-06-30 | 463.3 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 406.3 K | Private Advisor Group, Llc | 2024-09-30 | 373.1 K | Deerfield Management Co | 2024-06-30 | 322.9 K | Two Sigma Advisers, Llc | 2024-06-30 | 264.3 K | Aqr Capital Management Llc | 2024-06-30 | 256.3 K | Blackrock Inc | 2024-06-30 | 7.1 M | Vanguard Group Inc | 2024-09-30 | 5.1 M |
Humacyte Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Humacyte or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Humacyte's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Humacyte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | 2.03 | |
σ | Overall volatility | 5.07 | |
Ir | Information ratio | -0.1 |
Humacyte Volatility Alert
Humacyte exhibits very low volatility with skewness of 0.15 and kurtosis of 2.2. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Humacyte's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Humacyte's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Humacyte Fundamentals Vs Peers
Comparing Humacyte's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Humacyte's direct or indirect competition across all of the common fundamentals between Humacyte and the related equities. This way, we can detect undervalued stocks with similar characteristics as Humacyte or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Humacyte's fundamental indicators could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Humacyte to competition |
| Fundamentals | Humacyte | Peer Average |
| Return On Equity | -8.51 | -0.31 |
| Return On Asset | -0.53 | -0.14 |
| Current Valuation | 574.42 M | 16.62 B |
| Shares Outstanding | 128.67 M | 571.82 M |
| Shares Owned By Insiders | 26.86 % | 10.09 % |
| Shares Owned By Institutions | 30.01 % | 39.21 % |
| Number Of Shares Shorted | 17.25 M | 4.71 M |
| Price To Earning | 18.04 X | 28.72 X |
| Price To Book | 30.28 X | 9.51 X |
| Price To Sales | 153.91 X | 11.42 X |
| Gross Profit | 1.56 M | 27.38 B |
| EBITDA | (96.46 M) | 3.9 B |
| Net Income | (110.78 M) | 570.98 M |
| Cash And Equivalents | 189.04 M | 2.7 B |
| Cash Per Share | 1.84 X | 5.01 X |
| Total Debt | 58.11 M | 5.32 B |
| Debt To Equity | 0.36 % | 48.70 % |
| Current Ratio | 17.46 X | 2.16 X |
| Book Value Per Share | (0.53) X | 1.93 K |
| Cash Flow From Operations | (73.31 M) | 971.22 M |
| Short Ratio | 5.35 X | 4.00 X |
| Earnings Per Share | (1.34) X | 3.12 X |
| Target Price | 13.0 | |
| Number Of Employees | 183 | 18.84 K |
| Beta | 1.47 | -0.15 |
| Market Capitalization | 577.72 M | 19.03 B |
| Total Asset | 128.22 M | 29.47 B |
| Retained Earnings | (537.31 M) | 9.33 B |
| Working Capital | 64.83 M | 1.48 B |
| Net Asset | 128.22 M |
Note: Disposition of 716573 shares by Niklason Laura E of Humacyte at 7.78 subject to Rule 16b-3 [view details]
Humacyte Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Humacyte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Humacyte Buy or Sell Advice
When is the right time to buy or sell Humacyte? Buying financial instruments such as Humacyte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Humacyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Business Supplies Thematic Idea Now
Business Supplies
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Supplies theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Supplies Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Humacyte Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.